Aminophylline
Ethylenediamine-theophylline complex (2:1) in USP/EP/BP grade for oral tablet and injectable formulation manufacturing. Sourced for acute bronchospasm and respiratory stimulant product lines.
Pharmaceutical & Life Science Solutions
Xanthine bronchodilators and beta-2 agonists managing airway obstruction. Supplied in USP/EP/BP grade for tablet, injectable, and nebuliser formulation manufacturing across asthma and COPD product lines.
Ethylenediamine-theophylline complex (2:1) in USP/EP/BP grade for oral tablet and injectable formulation manufacturing. Sourced for acute bronchospasm and respiratory stimulant product lines.
Xanthine alkaloid in USP/EP/BP/JP grade for oral tablet and injectable formulation manufacturing. Sourced for neonatal apnoea and respiratory stimulant adjunct product lines.
Theophylline derivative (7-(2-hydroxyethyl)theophylline) in EP grade for injectable and oral formulation manufacturing. Sourced for bronchodilator combination product lines, distinct from parent theophylline.
Short-acting beta-2 agonist supplied as sulfate salt — the standard pharmacopoeial trading form, USP/EP grade — for MDI, DPI, nebuliser solution, and tablet formulation manufacturing.
Long-acting beta-2 agonist supplied as sulfate salt — the standard pharmacopoeial trading form, USP/EP grade — for tablet, injectable, and nebuliser solution formulation manufacturing.
Parent xanthine bronchodilator in USP/EP grade for oral tablet and extended-release capsule formulation manufacturing. Sourced for chronic asthma and COPD maintenance therapy product lines.